In the first of a two part investigation, Deborah used internal documents and US and EU regulatory documents obtained under freedom of information to find out what was known about the use of this oral anticoagulant. She found that the company had conducted analyses about how to make its use safer – but hadn’t shared these with global drug regulators. The story got international media coverage and led to regulatory¬†action.

https://www.bmj.com/content/349/bmj.g4670

Write A Comment